Even with many antidepressant and anxiolytic drugs available on the market, there are still patients who do not respond well to the standard first or second line treatments for affective or anxiety disorders. The antidepressant agomelatine has been used in Europe for several years. Agomelatine, an agonist at melatonin receptors and an antagonist at serotonin receptors, can be particularly useful in patients suffering from a major depressive disorder associated with insomnia. Some clinical data have shown a limited effect for agomelatine in a subset of patients with major depression. A number of case reports published in 2011-2016 describe the effect of agomelatine in combination with an established antidepressant, such as escitalopram, venlafaxine, duloxetine, moclobemide or bupropion. A successful combination of agomelatine was reported after adjunctive use of agomelatine combined with clomipramine, escitalopram, and venlafaxine in patients with major depression or obsessive-compulsive disorder. Moreover, bupropion or moclobemide augmentation with agomelatine in patients with major depressive disorder led to a significant improvement. Other supportive data have been published, such as analysis of the VIVALDI study, although it should be noted that the study was supported by the manufacturer of agomelatine. In this study, agomelatine in combination with other antidepressants was shown to be effective and well tolerated in practice, although the most effective antidepressant treatment in the study consisted of agomelatine alone and not in combination with other antidepressants. There have also been two published case reports about the concomitant use of duloxetine and agomelatine which were not efficacious. The positive results of agomelatine augmentation with other antidepressants should be confirmed through randomized, double-blind clinical trials.

Department of Pharmacology and Toxicology Charles University Faculty of Medicine in Pilsen alej Svobody 1655 76 323 00 Pilsen Czech Republic

Department of Pharmacology Charles University 3rd Faculty of Medicine Ruská 87 100 00 Prague 10 Czech Republic

Zobrazit více v PubMed

O’Leary OF, Dinan TG, Cryan JF. Faster, better, stronger: towards new antidepressant therapeutic strategies. Eur J Pharmacol 2015; 753: 32–50. PubMed

Korte SM, Prins J, Krajnc AM, et al. The many different faces of major depression: it is time for personalized medicine. Eur J Pharmacol 2015; 753: 88–104. PubMed

Millan MJ. On ‘polypharmacy’ and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. Int J Neuropsychopharmacol 2014; 17: 1009–1037. PubMed

Artigas F, Bortolozzi A, Celada P. Can we increase speed and efficacy of antidepressant treatments? Part I: general aspects and monoamine-based strategies. Eur Neuropsychopharmacol 2018; 28: 445–456. PubMed

Bares M, Novak T, Kopecek M, et al. Is combined treatment more effective than switching to monotherapy in patients with resistant depression? A retrospective study. Neuro Endocrinol Lett 2009; 30: 723–728. PubMed

McIntyre RS, Lee Y, Mansur RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr 2015; 20(Suppl 1): 20–30; quiz 1. PubMed

Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014; 29: 470–482. PubMed PMC

Citrome L. Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2016; 196: 225–233. PubMed

Connolly KR, Thase ME. Vortioxetine: a new treatment for major depressive disorder. Expert Opin Pharmacother 2016; 17: 421–431. PubMed

Baldwin DS, Florea I, Jacobsen PL, et al. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord 2016; 206: 140–150. PubMed

Thase ME, Mahableshwarkar AR, Dragheim M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol 2016; 26: 979–993. PubMed

Pae CU, Wang SM, Han C, et al. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci 2015; 40: 174–186. PubMed PMC

Guardiola-Lemaitre B, De Bodinat C, Delagrange P, et al. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol 2014; 171: 3604–3619. PubMed PMC

Fornaro M, Prestia D, Colicchio S, et al. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010; 8: 287–304. PubMed PMC

San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008; 23: 396–402. PubMed

Gahr M. Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks. Curr Neuropharmacol 2014; 12: 387–398. PubMed PMC

Koesters M, Guaiana G, Cipriani A, et al. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013; 203: 179–187. PubMed

Taylor D, Sparshatt A, Varma S, et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014; 348: g1888. PubMed PMC

Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 1357–1366. PubMed PMC

Chokka PR, Hankey JR. Assessment and management of sexual dysfunction in the context of depression. Ther Adv Psychopharmacol 2018; 8: 13–23. PubMed PMC

Montejo A, Majadas S, Rizvi SJ, et al. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol 2011; 26: 537–542. PubMed

De Berardis D, Serroni N, Marini S, et al. Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report. Case Rep Psychiatry 2012; 2012: 642752. PubMed PMC

Dahale AB, Narayanaswamy JC, Venkatasubramanian G, et al. Successful use of agomelatine and venlafaxine combination in major depression. Gen Hosp Psychiatry 2014; 36: e3. PubMed

Signorelli MS, Concerto C, Battaglia E, et al. Venlafaxine augmentation with agomelatine in a patient with obsessive-compulsive disorder and suicidal behaviors. SAGE Open Med Case Rep 2014; 2: 2050313×14561778. PubMed PMC

Suhs KW, Correll C, Eberlein CK, et al. Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group. Brain Behav 2015; 5: e00318. PubMed PMC

Stuhec M, Oravecz R. Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case. Wien Klin Wochenschr 2016; 128: 295–298. PubMed

Imboden C, Hatzinger M. Agomelatine-induced akathisia with concomitant duloxetine medication: a case report. Pharmacopsychiatry 2012; 45: 162–163. PubMed

Stuhec M. Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature. Wien Klin Wochenschr 2015; 127: 703–706. PubMed

Laux G, Huttner NA; VIVALDI study group. Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-naive patients, in combination therapy and after treatment switch. Int J Psychiatry Clin Pract 2014; 18: 86–96. PubMed

Da Rocha FF, Correa H. Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD. Clin Neuropharmacol 2011; 34: 139–140. PubMed

De Berardis D, Valchera A, Fornaro M, et al. Agomelatine reversal of escitalopram-induced apathy: a case report. Psychiatry Clin Neurosci 2013; 67: 190–191. PubMed

Yatham LN, Vieta E, Goodwin GM, et al. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry 2016; 208: 78–86. PubMed

Thomas J, Khanam R, Vohora D. Augmentation of antidepressant effects of venlafaxine by agomelatine in mice are independent of kynurenine pathway. Neurochem Int 2016; 99: 103–109. PubMed

Tzavellas E, Karaiskos D, Ilias I, et al. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report. Psychiatriki 2014; 25: 179–184. PubMed

Akpinar A, Uguz AC, Naziroglu M. Agomelatine and duloxetine synergistically modulates apoptotic pathway by inhibiting oxidative stress triggered intracellular calcium entry in neuronal PC12 cells: role of TRPM2 and voltage-gated calcium channels. J Membr Biol 2014; 247: 451–459. PubMed

Laux G; VIVALDI study group. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry 2012; 45:284–291. PubMed

Rang HP, Ritter JM, Flower RJ, et al. Antidepressant drugs. Rang and Dale’s pharmacology. 8th ed. London: Elsevier: 2016, pp. 570–588.

Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44: 195–235. PubMed

O’Donnell JM, Shelton RC. Drug therapy of depression and anxiety disorders. Goodman and Gilman’s pharmacological basis of therapy. 12th ed. New York: Mc Graw Hill Medical: 2011, pp. 397–415.

Freiesleben SD, Furczyk K. A systematic review of agomelatine-induced liver injury. J Mol Psychiatry 2015; 3: 4. PubMed PMC

Gahr M, Kratzer W, Fuchs M, et al. Safety and tolerability of agomelatine: focus on hepatotoxicity. Curr Drug Metab 2014; 15: 694–702. PubMed

Friedrich ME, Akimova E, Huf W, et al. Drug-induced liver injury during antidepressant treatment: results of AMSP, a drug surveillance program. Int J Neuropsychopharmacol 2016; 19: pii: pyv126. PubMed PMC

Voican CS, Corruble E, Naveau S, et al. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 2014; 171: 404–415. PubMed

Billioti de Gage S, Collin C, Le-Tri T, et al. Antidepressants and hepatotoxicity: a cohort study among 5 million individuals registered in the French national health insurance database. CNS drugs 2018; 32: 673–684. PubMed PMC

Laux G, Barthel B, Hajak G, et al. Pooled analysis of four non-interventional studies: effectiveness and tolerability of the antidepressant agomelatine in daily practice. Adv Ther 2017; 34: 895–914. PubMed

Fatouh AM, Elshafeey AH, Abdelbary A. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. Drug Des Devel Ther 2017; 11: 1815–1825. PubMed PMC

Molecular actions of sex hormones in the brain and their potential treatment use in anxiety disorders